Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot

Diabetic Neuropathy Clinical Trial

Official title:

A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01951859
• Other study ID #: NUC-DERM-0213-DFU
• Status: Recruiting
• Phase: N/A
• First received: September 16, 2013
• Last updated: July 22, 2014
• Start date: August 2013
• Est. completion date: February 2015

Study information

• Verified date: July 2014
• Source: Calvary Hospital, Bronx, NY
• Contact: Dr. Oscar Alvarez, PhD
• Phone: 732-672-7291
• Email: oalvarez[@]calvaryhospital.org
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This is a study whose primary objective is to assess the effectiveness of Neuropathy/Ulcer Cream in the promotion of healing skin fissures plantar foot ulcers and as a moisturizer to prevent dry skin turning into ulcers as compared with a placebo cream containing the same vehicle as Neuropathy/Ulcer Cream without the active ingredients (Control).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: February 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Patient is 18 years old or older.

2. Patient has a current diagnosis of diabetes (Type 1 or 2).

3. Patient's fissure or foot ulcer is on the plantar surface of the foot.

4. Patient's fissure or ulcer is at least a partial thickness wound extending through the epidermis and at least part of the dermis. The wound may extend through the dermis and into subcutaneous tissue (granulation tissue may be present), but without exposure of muscle, tendon, bone, or joint capsule (Wagner Grade 1).

5. Patient's wound is free of necrotic debris and clinical infection, should be comprised of healthy, vascular tissue.

6. Patient's Ankle-Brachial Index (ABI) by Doppler is 0.7.

7. The patient has adequate circulation to the foot to allow for healing.

This must be demonstrated by either of the following methods:

The patient has a palpable pulse on the study foot (either dorsalis pedis, posterior tibial, or peroneal artery) and has clinical signs of adequate circulation in the foot (e.g., toes are warm and pink).

If either there are no palpable pulses or clinical signs of adequate circulation are lacking, the Investigator must perform an additional assessment to assure that there is adequate circulation to the foot. Transcutaneous oxygen tension (TcPo2), photoplethysmography (PPG), Toe-Arm Index, Doppler wave form, Cardiosynchronous Limb Compression (CSC), Pulse Volume Recording (PVR) or exercise Ankle-Brachial Index (ABI). Determination of adequate circulation must be according to generally accepted criteria for the particular test employed. The additional assessments must be documented in the patient's source document and Case Report Form.

8. Patient's diabetes is under control as determined by the Investigator from daily glucometer diary entries.

9. Patient and caregiver are willing to participate in the clinical study and can comply with the follow-up regimen.

10.Patient or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment.

Exclusion Criteria:

1. Patient has clinical evidence of gangrene on any part of the affected foot.

2. The patient's ulcer is due to a nondiabetic etiology. Ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease,or other nondiabetic etiologies are not to be enrolled.

3. Patient's ulcer has tunnels or sinus tracts that cannot be completely debrided.

4. Patient's diabetes is uncontrolled and could interfere with the completion of the study.

5. Patient has one or more medical condition(s), including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the Investigator would make the patient an inappropriate candidate for this wound healing study.

6. Patient has or has had a malignant disease (other than cutaneous epithelioma) not in remission for five years or more.

7. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study.

8. Patient has Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV).

9. Patient has participated in another study utilizing an investigational drug or device within the previous 30 days.

10. Patient's ulcer is infected or accompanied by active cellulitis, osteomyelitis as determined by the investigator

11. Patient has any condition(s) that seriously compromises the patient's ability to complete this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Neuropathies
• Diabetic Neuropathy

Intervention

Other:
• Neuropathy/Ulcer Homeopathic topical cream
This is a GRAS topical agent containing homeopathic ingredients

Locations

Country	Name	City	State
United States	Calvary Hospital Wound Care Clinic	Bronx	New York

Sponsors (1)

Lead Sponsor	Collaborator
Calvary Hospital, Bronx, NY

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decrease in area or closure of wounds/fissures due to Homeopathic Anti-inflammatory Topical Cream		12 weeks or wound closure	No